X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES VENUS REMEDIES SUVEN LIFESCIENCES/
VENUS REMEDIES
 
P/E (TTM) x 17.8 -0.9 - View Chart
P/BV x 3.6 0.1 5,333.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUVEN LIFESCIENCES   VENUS REMEDIES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
VENUS REMEDIES
Mar-18
SUVEN LIFESCIENCES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs338126 268.2%   
Low Rs16961 277.3%   
Sales per share (Unadj.) Rs52.1301.8 17.3%  
Earnings per share (Unadj.) Rs6.8-24.9 -27.5%  
Cash flow per share (Unadj.) Rs8.62.5 336.8%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.3293.3 22.3%  
Shares outstanding (eoy) m127.2812.34 1,031.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.90.3 1,569.9%   
Avg P/E ratio x37.1-3.8 -987.3%  
P/CF ratio (eoy) x29.636.7 80.5%  
Price / Book Value ratio x3.90.3 1,218.2%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,2721,154 2,797.0%   
No. of employees `0001.10.9 117.0%   
Total wages/salary Rs m661393 168.2%   
Avg. sales/employee Rs Th6,132.24,026.1 152.3%   
Avg. wages/employee Rs Th611.1425.0 143.8%   
Avg. net profit/employee Rs Th803.5-331.8 -242.2%   
INCOME DATA
Net Sales Rs m6,6353,724 178.2%  
Other income Rs m24223 1,076.8%   
Total revenues Rs m6,8773,747 183.6%   
Gross profit Rs m1,604395 406.3%  
Depreciation Rs m221338 65.4%   
Interest Rs m38354 10.6%   
Profit before tax Rs m1,587-275 -576.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m71832 2,272.1%   
Profit after tax Rs m869-307 -283.3%  
Gross profit margin %24.210.6 228.1%  
Effective tax rate %45.2-11.5 -394.0%   
Net profit margin %13.1-8.2 -159.0%  
BALANCE SHEET DATA
Current assets Rs m6,2322,638 236.3%   
Current liabilities Rs m1,4902,305 64.7%   
Net working cap to sales %71.58.9 799.2%  
Current ratio x4.21.1 365.4%  
Inventory Days Days86135 63.8%  
Debtors Days Days8346 178.3%  
Net fixed assets Rs m4,0434,871 83.0%   
Share capital Rs m127123 103.2%   
"Free" reserves Rs m8,1833,496 234.1%   
Net worth Rs m8,3103,619 229.6%   
Long term debt Rs m181,374 1.3%   
Total assets Rs m10,3897,509 138.4%  
Interest coverage x43.10.2 19,332.3%   
Debt to equity ratio x00.4 0.6%  
Sales to assets ratio x0.60.5 128.8%   
Return on assets %8.70.6 1,383.1%  
Return on equity %10.5-8.5 -123.4%  
Return on capital %19.51.6 1,233.5%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m5,6220-   
Fx outflow Rs m1,799517 348.4%   
Net fx Rs m3,822-517 -740.0%   
CASH FLOW
From Operations Rs m356514 69.1%  
From Investments Rs m-279-123 226.3%  
From Financial Activity Rs m-225-387 58.2%  
Net Cashflow Rs m-1484 -3,528.6%  

Share Holding

Indian Promoters % 63.4 32.9 193.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 66.4 55.0%  
Shareholders   37,287 20,121 185.3%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

One Stock You Could Consider Buying Now and Holding Forever(The 5 Minute Wrapup)

Aug 22, 2019

If there is one company that I could recommend that is making the most of the tech disruption, this would be it.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 23, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS